Orthopaedic knee implants Current Affairs - 2020
Category Wise PDF Compilations available at This Link
Government has notified that ceiling price of orthopaedic knee implants will be monitored to ensure that their cost does not increase beyond 10% in a given year.
Earlier on 16 August 2017, National Pharmaceutical Pricing Authority (NPPA) notified ceiling price of orthopaedic knee implants by invoking extraordinary powers, in public interest, under Para 19 of Drugs Prices Control Order (DPCO) 2013, for a period of 1 year. Subsequently a notification was issued dated 13 August 2018, the applicability of ceiling prices fixed for orthopaedic knee implants was extended for another 1 year period i.e. up to 15 August 2019.
This led to the reduction in cost of knee implants significantly, up to 69%, resulting in a notional saving of Rs.1500 crore per annum to consumers.
At a meeting held on 8 August 2019, NPPA reviewed the sales of knee implants matter and noted that there has been an increased access due to knee implants becoming affordable. As per data submitted by manufacturers and importers, during period of July 2018 to June 2019, an increase of 30% in sales of knee implants was reported.
Though the medical industry has requested for a 20% (10% for year 2018 and 10% for 2019) increase in price of knee implants, government decided to further monitor price increase of knee implants as per para 20 of Drugs Prices Control Order (DPCO) 2013 that restricts price increase beyond 10% in a given year which shall be subject to a review after 1 year period.
About Knee Implant:
It is a non-scheduled medical device or drug for which Drugs Prices Control Order (DPCO), 2013 allows an annual increase upto 10% of MRP (Maximum retail price). However this was not permitted in 2018.
What is National Pharmaceutical Pricing Authority?
NPPA is independent body of experts that controls prices of pharmaceutical drugs in India. It is government regulatory agency formed on 29 August 1997.
It functions under Union Ministry of Chemicals and Fertilizers to implement and enforce provisions of Drugs Prices Control Order (DPCO) for regulating medicine prices in accordance with powers delegated to it.
DPCO is an order issued by government under ‘Essential Commodities Act’ which enables it to fix prices of some essential bulk drugs as well as their formulations.
Tags: Ceiling Price • Drugs Prices Control Order (DPCO) 2013 • Essential Commodities Act • Knee Implant • National Pharmaceutical Pricing Authority
The drug price regulator National Pharmaceuticals Pricing Authority (NPPA) has capped the prices of orthopaedic knee implants upto 70% lower than current market rates.
It will be valid for all orthopaedic knee implants sold within India – whether domestic or imported. Earlier in February 2017, the NPPA had capped the prices of stents used in cardiac surgery.
According to World Health Organization (WHO) estimation, osteoarthritis is going to be the fourth largest cause of immobility in globally by 2020. NPPA in its preliminary analysis had found that importers, distributors and hospitals are earning hefty trade margins ranging from 67% to as high as 449% orthopaedic knee implants.
Now, the most widely used Cobalt chromium knee implant will cost around Rs. 55000 instead of current average price of over Rs. 1.58 lakh. Titanium Oxidized Zirconium surgery implant has been capped at Rs.76,600 against the current average prices of Rs.2.5 to 4.50 lakh. The High flexibility implant costing from Rs. 1.80 to 4.5 lakh has been capped at Rs. 56,490. The revision implants for second surgery has been capped at over Rs. 1.13 lakh. Besides, the Specialized implants for cancer and tumor will be charged at over Rs. 1.13 lakh.
This decision has been taken keeping people’s interest and health security of the nation into consideration. It is considered as a major relief to patients suffering from knee problems. It will help check unethical profiteering in the implant surgery. It will benefit around 1.5 to 2 crore knee patients and result in savings of Rs 1,500 crore annually to patients requiring surgery.
National Pharmaceutical Pricing Authority (NPPA)
NPPA is an independent body under Department of Pharmaceuticals under the Union Ministry of Chemicals and Fertilizers. Its functions are to fix/revise the controlled bulk drugs prices and formulations, enforce prices and availability of the medicines under the Drugs (Prices Control) Order, 1995/2013, recover amounts overcharged by manufacturers for the controlled drugs from the consumers and monitor the prices of decontrolled drugs in order to keep them at reasonable levels.
Tags: Drug Pricing • Health Security • NPPA • Orthopaedic knee implants • Public Health